SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)
Phase of Trial: Phase IV
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms SEESAW
- Sponsors Boehringer Ingelheim
- 07 Jun 2017 Biomarkers information updated
- 04 Aug 2016 Planned initiation date changed from 1 Jul 2016 to 1 Sep 2016.
- 27 Jul 2016 Status changed from not yet recruiting to recruiting.